Rivastigmine Chemical Structure (Exelon Patch 01)
Exelon Patch, Extended Release
Product Images NDC 0078-0502
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Exelon (NDC 0078-0502). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Cross Section Of The Exelon Patch (Exelon Patch 02)
Figure 2: Rivastigmine Plasma Concentrations Following Dermal 24-hour Patch Application (Exelon Patch 03)
This is a table of Rivastigmine levels in ng/mL among 63 individuals with different doses: 19 individuals had a dose of 13.3 mg/24 hours, 22 individuals had a dose of 9.5 mg/24 hours, and 22 individuals had a dose of 4.6 mg/24 hours.*
Figure 3: Time Course Of The Change From Baseline In Adas-cog Score For Patients Observed At Each Time Point (Exelon Patch 04)
Figure 4: Distribution Of Adcs-cgic Scores For Patients Completing The Study (Exelon Patch 05)
Figure Aapply One Patch To Only One Of The Following Possible Sites Each Day (Exelon Patch 06)
This appears to be a description of a patch used for transdermal medication delivery. It contains 1 system for delivering the medication fivastigmine. The product is called Exelon Patch and has protective liners and adhesive for use on the skin.*
Cut The Pouch Along The Dotted Line And Remove The Patch. (Exelon Patch 07)
This text appears to be a list of body parts on which an activity or measurement can be performed. Specifically, it mentions the left or right upper arm, the left or right side of the chest, the side (with no indication of right or left), the left or right upper back, and the left or right lower back. It is possible that these body parts are relevant to a medical procedure, workout routine, or other activities that require a focus on certain areas of the body.*
A Protective Liner Covers The Adhesive Side Of The Patch. Peel Off One Side Of The Protective Liner And Do Not Touch The Sticky Part Of The Patch With The Fingers. (Exelon Patch 08)
Put The Sticky Side Of The Patch On The Upper Or Lower Back, Upper Arm Or Chest And Then Peel Off The Second Side Of The Protective Liner. (Exelon Patch 09)
Press The Patch Firmly In Place With The Hand To Make Sure That The Edges Stick Well. (Exelon Patch 0a)
Principal Display Panelpackage Label – 4.6 mg / 24 Hoursrx Only Ndc 0078-0501-15exelon® Patch(rivastigmine Transdermal System) Each System Delivers 4.6 mg/24 Hoursfor Transdermal Use Onlycontains 30 Systems (Exelon Patch 0b)
Principal Display Panelpackage Label – 9.5 mg / 24 Hoursrx Only Ndc 0078-0502-15exelon® Patch(rivastigmine Transdermal System) Each System Delivers 9.5 mg/24 Hoursfor Transdermal Use Onlycontains 30 Systems (Exelon Patch 0c)
ExelonPatch is a chosen transdermal system that contains 30 patches with an active ingredient called rivastigmine. The patch is designed to provide 9.5 mg of medication over a 24-hour period. The text also includes some illegible characters and numbers that appear to be related to a product code.*
Figure 5 Time Course Of The Change From Double-blind Baseline In Adcs-iadl Score For Patients Observed At Each Time Point In Study 2 (Exelon Patch 0d)
Figure 6 Time Course Of The Change From Double-blind Baseline In Adas-cog Score For Patients Observed At Each Time Point In Study 2 (Exelon Patch 0e)
Principal Display Panelpackage Label – 13.3 mg / 24 Hoursrx Only Ndc 0078-0503-15exelon® Patch(rivastigmine Transdermal System) Each System Delivers 13.3 mg/24 Hoursfor Transdermal Use Onlycontains 30 Systems (Exelon Patch 0f)
Not available. The text appears to be a mixture of letters and random characters that do not form a coherent description.*
Figure 7 Time Course Of The Change From Baseline In Sib Score For Patients Observed At Each Time Point (modified Full Analysis Set – Locf) (Exelon Patch 0g)
This is a data table presenting the LS mean difference improvement for Rivastigmine patch at two different sizes (1 cm and 5 cm) over a period of 16 weeks of treatment. The table displays statistical significant differences between the two patch sizes at p<.0001. The LS means and standard errors are based on an analysis of the covariance model adjusted for center and baseline.*
Figure 8 Time Course Of The Change From Baseline In Adcs-adl-siv Score For Patients Observed At Each Time Point (modified Full Analysis Set – Locf) (Exelon Patch 0h)
The text represents statistical data related to the clinical trial of Rastigmine patch treatment over a course of few weeks. The data showcases the LS mean di Improvement in patients who underwent the treatment along with statistical significance. The text also mentions the LS Mean Change and Standard Errors based on the analysis of covariance model adjusted for baseline and pooled center.*
Figure F (Exelon Patch 0i)
Figure G (Exelon Patch 0j)
Figure H (Exelon Patch 0k)
This appears to be a set of instructions for disposing of a slide folded patch. The patch should be placed in the trash, but first the sticky sides should be folded together and placed in an empty pouch that should be kept away from children and pets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
